{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-239601","form_type":"8-K","ticker":"ZYME","cik":"0001937653","company_name":"Zymeworks Inc.","filed_at":"2023-09-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.095415+00:00","generated_at":"2026-06-10T11:19:56.199564+00:00","sec_items":["1.02","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Zymeworks terminates ZW49 collaboration with BeiGene; ZW25 royalties reduced 0.5% until low double-digit million cap","bullets":["Termination of ZW49 license with BeiGene ends potential $195M milestones and high single-digit to 20% royalties in Asia, Australia, NZ.","Rights to zanidatamab zovodotin (ZW49) revert to Zymeworks.","Third Amendment to ZW25 deal reduces royalties by 0.5% until cumulative cap (low double-digit millions) reached.","No other changes to ZW25 agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-239601","json":"https://secwatch.observer/filing/0001193125-23-239601.json","markdown":"https://secwatch.observer/filing/0001193125-23-239601.md","text":"https://secwatch.observer/filing/0001193125-23-239601.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937653/000119312523239601/0001193125-23-239601-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937653/000119312523239601/d549533d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T11:19:56.199564+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"65fa4cad5ab65dafd905a27cee6f201642760cb0","claim":"Zymeworks Inc. terminated Zanidatamab Zovodotin License and Collaboration Agreement with BeiGene, Ltd. valued at up to $195 million in development and commercial milestone payments and royalties ranging from the h (effective 2023-09-18).","evidence_excerpt":"On September 18, 2023, Zymeworks BC Inc. (“Zymeworks BC”), a subsidiary of Zymeworks Inc. (the “Company”), and BeiGene, Ltd. (“BeiGene”) entered into a Termination Agreement (the “Termination Agreement”) relating to the License and Collaboration Agreement between Zymeworks BC and BeiGene, relating to the research, development and commercialization of zanidatamab zovodotin (formerly known as ZW49), dated November 26, 2018, as amended on May 25, 2020 and June 2, 2021 (collectively, the “Zanidatamab Zovodotin License and Collaboration Agreement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1937653/000119312523239601/0001193125-23-239601-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"BeiGene, Ltd."},{"label":"Value","value":"up to $195 million in development and commercial milestone payments and royalties ranging from the h"},{"label":"Effective","value":"2023-09-18"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}